Related Experiment Video
Updated: Nov 7, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.3K
Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the
Philip J Mease1,2, Apinya Lertratanakul3, Kim A Papp4
1Department of Rheumatology, Providence St. Joseph Health and University of Washington, Seattle, WA, USA. pmease@philipmease.com.
Rheumatology and Therapy
|April 29, 2021
Summary
Upadacitinib maintained efficacy for psoriatic arthritis (PsA) patients over 56 weeks. This Janus kinase inhibitor showed no new safety concerns in patients with prior biologic treatment failure.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Psoriatic arthritis (PsA) is a chronic inflammatory condition.
- Biologic therapies are common treatments for PsA.
- Some patients do not respond adequately or tolerate existing biologic therapies.
Purpose of the Study:
- To assess the 56-week efficacy and safety of upadacitinib in PsA patients.
- To evaluate upadacitinib in patients with an inadequate response or intolerance to biologic therapy.
Main Methods:
- Phase 3 SELECT-PsA 2 study involving 641 patients.
- Randomized, double-blind treatment with oral upadacitinib (15 or 30 mg daily) or placebo.
- Placebo group switched to upadacitinib at week 24; treatment duration was 56 weeks.
Main Results:
- Efficacy improvements (ACR20/50/70, PASI75/90/100, minimal disease activity) were maintained through 56 weeks.
- Patients switching from placebo to upadacitinib showed similar outcomes.
- Serious infection rates were 2.6 and 6.1 events/100 patient-years for 15 and 30 mg upadacitinib, respectively. Herpes zoster was more frequent with the 30 mg dose.
Conclusions:
- Upadacitinib demonstrated sustained efficacy in PsA patients over 56 weeks.
- No new significant safety signals were identified.
- Upadacitinib is a viable treatment option for PsA patients with prior biologic treatment failure.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
277
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
277
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
302
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
302
01:20The JAK-STAT Signaling Pathway
9.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.9K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
305
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
305
01:29Inflammatory Bowel Disease IV: Pharmacological Management
261
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
261
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
268
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
268